Jack M. Gorman, MD: Merging the Cognitive Behavioral and Psychopharmacological Paradigms in Comparative Studies: Controversies, Issues, and Some Solutions

Name: Jack M. Gorman, MD: Merging the Cognitive Behavioral and Psychopharmacological Paradigms in Comparative Studies: Controversies, Issues, and Some Solutions
SKU: 3360
Availability: InStock

$30.00

Want a discount? Become a member by purchasing Psychopharmacology Bulletin Subscription - Individual!

Categories: Psychopharmacology Bulletin, VOL 35 No. 2 Articles Tags: cognitive-behavioral-therapy-cbt, comparative-studies, david-h-barlow, imipramine, jack-m-gorman, m-katherine-shear, medworks-media, panic-disorder-pd, psychopharmacology-bulletin, scott-woods, susan-ray

Description

Jack M. Gorman, MD: Merging the Cognitive Behavioral and Psychopharmacological Paradigms in Comparative Studies: Controversies, Issues, and Some Solutions

Description

Jack M. Gorman, MD

GENERAL PSYCHOPHARMACOLOGY

Merging the Cognitive Behavioral and Psychopharmacological Paradigms in Comparative Studies: Controversies, Issues, and Some Solutions

Jack M. Gorman, MD, David H. Barlow, PhD, Susan Ray, M. Katherine Shear, MD, and Scott Woods, MD

Paliperidone Double-blind, Placebo- and Active-Controlled, Study

Clozapine Related Suicidal Obsession by Branka Aukst-Margetic

What Mood Symptoms may be most Difficult to Rate?

Schizophrenia Rating Scales Critical Review by Takefumi Suzuki

Jack M. Gorman, MD: Merging the Cognitive Behavioral and Psychopharmacological Paradigms in Comparative Studies: Controversies, Issues, and Some Solutions

Description

Jack M. Gorman, MD

GENERAL PSYCHOPHARMACOLOGY

Merging the Cognitive Behavioral and Psychopharmacological Paradigms in Comparative Studies: Controversies, Issues, and Some Solutions

Jack M. Gorman, MD, David H. Barlow, PhD, Susan Ray, M. Katherine Shear, MD, and Scott Woods, MD

Related products

Paliperidone Double-blind, Placebo- and Active-Controlled, Study

Clozapine Related Suicidal Obsession by Branka Aukst-Margetic

What Mood Symptoms may be most Difficult to Rate?

Schizophrenia Rating Scales Critical Review by Takefumi Suzuki